Nina S Kjellson
CIK 1381980 · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TSRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2710 SAND HILL ROAD, SUITE 200
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELOX | Director | — | $13.17 | — | $0 | 1 | 2026-06-10 |
| TYRA | Director | 443,885 | $20.42 | $9.06M | -$4.41M | 12 | 2025-02-07 |
| Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Director | — | $1.73 | — | $0 | 3 | 2017-04-14 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 67,841 | $221.38 | $15.02M | $3.20M | 1 | 2015-04-22 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 3,548,643 | — | — | $6.14M | 5 | 2013-05-23 |
| Marketo, Inc. (MKTO) Delisted | 10%+ Owner | 9,747,191 | — | — | $0 | 1 | 2013-05-22 |
Recent Filings · Page 3 of 4
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-04-22 | Cidara Therapeutics, Inc. (CDTX) Delisted | Mixed | +1,356,813 | $3.20M | EDGAR |
| 2013-12-23 | — | Grant (A) | — | $0 | |
| 2013-11-12 | — | Buy (P) | +422,238 | $0 | |
| 2013-09-13 | — | Disp (D) | — | $0 | |
| 2013-07-17 | — | Mixed | +825,826 | $2.60M | |
| 2013-05-23 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-22 | Marketo, Inc. (MKTO) Delisted | Conv (C) | +87,724,719 | $0 | EDGAR |
| 2012-05-24 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-06 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-11-05 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.